Gregory MacMichael

Dr. MacMichael has nearly 40 years of biopharmaceutical experience, including in the development and manufacturing of biologics. Most recently, he was Chief Technology Officer of Castle Creek Biosciences, Inc., and President of CMC Bioservices, a consultancy focused on the development and manufacturing of cell and gene therapies, biologics, and vaccines. Previously, he served as the Senior Vice President of Technology for Axovant Sciences, Senior Vice President of Development, Manufacturing, and Quality Control at NantKwest, and Senior Vice President of Process, Development, Manufacturing, and Quality Assurance at Rocket Pharma. He has also served as the Global Head of Biologics Process Development at Novartis, leading the chemistry, manufacturing, and control (CMC) aspects of Novartis’ acquisition and transfer of Kymriah® from the University of Pennsylvania, including building the supply chain for plasmids, lentiviral vector, and production capacity. Dr. MacMichael has worked with various notable companies, including Novartis, Wyeth, Eli Lilly, Chiron, Centocor, and Cook. Dr. MacMichael received his Ph.D. in microbiology/biochemistry from Mississippi State University, his M.S. in microbiology/biochemistry from North Carolina State University, and his B.S. in microbiology from Pennsylvania State University.